Long Non-Coding RNA LINC00152 Regulates Self-Renewal of Leukemia Stem Cells and Induces Chemo-Resistance in Acute Myeloid Leukemia

Chunhong Cui1,2, Yan Wang3, Wenjie Gong4, Haiju He4, Hao Zhang3, Wei Shi3* and Hui Wang1*†

1 Shanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Shanghai, China, 2 Laboratory of Tumor Molecular Biology, School of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai, China, 3 Huashan Hospital, Fudan University, Shanghai, China, 4 Department of Hematology, First Affiliated Hospital of Soochow University, Suzhou, China

Relapse of acute myeloid leukemia (AML) has a very poor prognosis and remains a common cause of treatment failure in patients with this disease. AML relapse is partially driven by the chemoresistant nature of leukemia stem cells (LSCs), which remains poorly understood, and our study aimed at elucidating the underlying mechanism. Accumulating evidences show that long noncoding RNAs (lncRNAs) play a crucial role in AML development. Herein, the lncRNA, LINC00152, was identified to be highly expressed in CD34+ LSCs and found to regulate the self-renewal of LSCs derived from AML patients. Importantly, LINC00152 upregulation was correlated with the expression of 16 genes within a 17-gene LSC biomarker panel, which contributed to the accurate prediction of initial therapy resistance in AML. Knockdown of LINC00152 markedly increased the drug sensitivity of leukemia cells. Furthermore, LINC00152 expression was found to be correlated with poly (ADP-ribose) polymerase 1 (PARP1) expression in AML, whereas LINC00152 knockdown significantly decreased the expression of PARP1. Upregulation of LINC00152 or PARP1 was associated with poor prognosis in AML patients. Collectively, these data highlight the importance and contribution of LINC00152 in the regulation of self-renewal and chemoresistance of LSCs in AML.

Keywords: leukemia stem cells, LINC00152, poly (ADP-ribose) polymerase 1, chemo-resistance, leukemia

INTRODUCTION

Acute myeloid leukemia (AML) is a heterogeneous and deadly disease characterized by aberrant myeloid lineage cell proliferation and differentiation (1). Although most AML patients achieve remission, up to 70% of adults and 30% of pediatric patients do not survive beyond 5 years after the initial clinical response due to relapse (2). Historically, the relapse of AML patients has been attributed to the pre-existence of chemoresistant leukemia stem cells (LSCs) (3, 4). Nevertheless, the mechanisms underlying LSC-mediated leukemia relapse have not been elucidated. Leukemia cells differentiate from LSCs (5), which have the capacity to initiate leukemia in immunocompromised mice. Therefore, it is warranted to investigate potential factors contributing to the self-renewal and chemoresistant nature of LSCs.
Long noncoding RNAs (lncRNAs) have been identified in whole transcriptome sequencing projects, such as gene expression profiling interactive analysis (GEPIA). The established functions of lncRNAs include cell cycle regulation, lineage differentiation, and cancer progression (6–8). Deregulated expression of lncRNAs often occurs in AML (9, 10), which has been reported to be independently associated with AML patient prognosis (9, 11, 12). Although lncRNAs have been identified to regulate leukemia progression (13–15), their detailed role in chemoresistance remains unknown. LINC00152 is an lncRNA located at chromosome 2p11.2. Recently, LINC00152 was identified as a potent oncogene in various cancers (16, 17). In particular, LINC00152 expression has been reported to be upregulated in AML samples and facilitate AML leukemogenesis (18); nevertheless, its underlying mechanism needs to be further investigated.

Considering the high expression of LINC00152 in CD34+ LSCs and its regulatory role in LSC self-renewal, we hypothesized that LINC00152 could have biological significance in LSC chemoresistance, and the present study was performed with an aim to elucidate this significance. The inhibition of LINC00152 was found to increase the sensitivity of leukemia cells to doxorubicin. Furthermore, LINC00152 expression was correlated with the expression of poly (ADP-ribose) polymerase 1 (PARP1), whereas LINC00152 knockdown markedly decreased PARP1 expression. Thus, our results indicate that LINC00152 may serve as a potential prognostic marker for AML patients.

MATERIAL AND METHODS

Cell Culture

Cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and were cultured in a humidified incubator at 37°C and 5% CO₂. 293T cells (ATCC CRL-3216) were cultured in Iscove’s modified Dulbecco’s medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS) (Biochrom GmbH, Berlin, Germany) and digested with trypsin-EDTA (Sigma-Aldrich, St. Louis, MO, USA). K562 cells (ATCC CCL-243) were cultured in RPMI-1640 (Sigma-Aldrich) supplemented with 10% FBS (Biochrom GmbH, Berlin, Germany). Cells were grown in log-phase (1 × 10⁷–1 × 10⁸ cells/ml).

Bone Marrow Cells Isolation

Bone marrow specimens were collected from 15 adult AML patients and analyzed after obtaining written informed consent in accordance with the Declaration of Helsinki. Bone marrow cells were obtained at the diagnosis of adult patients with AML assessed at the Huashan Hospital of Fudan University, Shanghai, China. Bone marrow samples were collected in 10-ml syringes with 10.000IE/20 ml heparin after bone marrow puncture.

Flow Cytometry

Bone marrow cells were incubated with Alexa Fluor 488 anti-human CD34 antibody and phycoerythrin anti-human CD38 antibody (both from Biolegend, San Diego, CA, USA) diluted in magnetic-activated cell sorting buffer for 15 min on ice. The staining process was performed under a hood in the dark. After incubation, the cells were washed with phosphate-buffered saline (PBS). Stained cells were kept on ice before sorting. The concentration of the cells was adjusted to approximately 1 × 10⁶ cells/ml. Sorted cells were collected and freshly filtered, with PBS containing 2% FBS used as the catch medium. Acquisition was performed using an LSR II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). FlowJo software (BD Biosciences) was used for data analysis.

Colony Formation Assay

Methylcellulose (Stemcell Technologies, Vancouver, BC, Canada) was placed at room temperature for 30 min before usage. Each selected human LSC was adjusted to a concentration that was 10-fold higher than the final plating concentration. The cell suspension (300 µl) was mixed well with 3-ml methylcellulose at a density of 300 cells per ml of methylcellulose. After removing the air bubbles, the mixture was transferred to a 12-well plate with three replicates for each cell. Colonies (> 50 cells) were stained with trypan blue and counted under a microscope after 10 days.

Small Hairpin RNA (shRNA) and Plasmid Cloning

LINC00152 shRNAs were cloned into the pLKO.1_GFP vector with BamHI and AgeI restriction sites. The hairpin was synthesized by Sangon Biotech. The empty vector was recovered after digestion with BamHI and AgeI. The annealed hairpin and digested vector were ligated with T4 ligase (Thermo Fisher Scientific), and the ligating product was then transformed into Escherichia coli. The shRNA-targeting sequences were as follows: forward, CACAGCGCGGATGAGCTGAA and reverse, CCACGTGGACTCTGAGCCT.

Lentivirus Package and Leukemia Cell Infection

PLKO.1_GFP vector and packaging vectors (PLP1, PLP2, and VSVG) were transfected into 293T cells using Turbofect reagent (Thermo Fisher Scientific). After 48 h, supernatants with lentivirus particles were collected by ultracentrifugation. AML cells were transduced by incubation with the viral particles in the presence of polybrene (8 µg/ml, Sigma-Aldrich). The viral titers were then determined by flow cytometry 48 h following transduction.

RNA Isolation, Reverse Transcription, and Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)

AML cells were prepared by centrifugation, and total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific), followed by removal of genomic DNA. Complementary DNA was reverse transcribed using PrimeScript RT Reagent Kit (Thermo Fisher Scientific). qRT-PCR was performed with SYBR Green Master Mix (Bio-Rad, Hercules, CA, USA) on a StepOnePlus Real-Time PCR system (Thermo Fisher Scientific). The primers used for targeting LINC00152 were (forward) TGCCACAGCTCTTTCTCAGTCA and (reverse) TCAAGGGTTCGCCAGGCTG, whereas for PARP1 they were (forward) ACTGACATAGAAGGGCTTGAG and (reverse) GGGGAA ACCAGTAAGGCGAC.
Drug Sensitivity Assay
K562 cells (control and LINC00152 shRNA) were seeded onto 24-well plates at a density of 2.5 × 10⁴ viable cells/well in triplicate and treated with doxorubicin at the indicated concentrations. Cells were counted and analyzed after 3 days using a cell counting plate under a microscope.

Statistical Analyses
Statistical analyses were performed using SPSS version 22 (IBM Corp., Armonk, NY, USA) and R studio 3.5.0 (R Foundation, Vienna, Austria). Student’s t-test or one-way analysis of variance (ANOVA) was used to identify statistical significance. For Kaplan-Meier survival analysis, the log-rank test was used to determine statistical significance. Statistical significance was set at P < 0.05.

RESULTS
LINC00152 Is Highly Expressed in LSCs and Correlated With Poor AML Patient Prognosis
Evidence from a previous study suggests that CD34⁺CD38⁻ stem cells are the leading cause of chemoresistance (19). To investigate the role of this stem cell population in AML, bone marrow cells from 15 paired AML patients were collected, and the CD34⁺CD38⁻ and CD34⁺CD38⁺ subpopulations were sorted using flow cytometry (Figure 1A). Notably, CD34⁺CD38⁻ cells possessed a markedly stronger capacity for colony formation than CD34⁺CD38⁺ cells derived from paired 15 AML patients (P = 5.4 × 10⁻¹³) (Figure 1B). qRT-PCR showed that LINC00152 was highly expressed in CD34⁺CD38⁻ cells compared with CD34⁺CD38⁺ subpopulations (P = 0.02) (Figure 1C). Furthermore, GEPIA, based on The Cancer Genome Atlas (TCGA) data, was performed to determine the functions of LINC00152. Overall, high expression of LINC00152 was associated with poor AML patient survival (Figure 1D), suggesting that LINC00152 may be a potential prognostic marker for AML.

Correlation Between LINC00152 and LSC-Associated Gene Expression
Comprehensive analysis of LSC gene expression signatures was previously performed in 78 AML patients and validated by xenotransplantation, which generated a 17-gene LSC (LSC17) biomarker panel (ZBTB46, SOCS2, SMIM24, NGFRAP1, MMRN1, LAPT4M, DNMT3B, CPXM1, AKR1C3, CDK6, CD34, ARHGAP22, DPR56, NYNIRN, KIAA0125, EMP1, and DPYSL3). Moreover, Ng et al. reported that patients with high LSC17 scores had poor prognosis with current treatments, including allogeneic stem cell transplantation (20). To test whether LINC00152 expression correlates with the LSC17 gene signature, GEPIA was performed, which revealed that the expression of 15 of the 17 genes was significantly associated with that of LINC00152 (Figure 2). Two uncorrelated genes (EMP1, P = 0.6; and DPYSL3, P = 0.69) are not shown. These results suggest an important role of LINC00152 in leukemic stemness.

Repression of Colony Formation by LINC00152 Knockdown In CD34⁺ AML Cells
LINC00152 upregulation in LSCs and the observed correlation between LINC00152 and the LSC17 biomarker profile suggested its possible biological contribution toward the stemness of LSCs. To explore the influence of LINC00152 on LSC stemness, knockdown of LINC00152 using targeted shRNAs (sh00152#1 and sh00152#2) was performed. qRT-PCR analysis confirmed that both shRNAs significantly decreased the expression of LINC00152 compared with control non-targeted shRNA (Figure 3A). Colony formation assay is a well-characterized and validated method to assess the differentiation and proliferation ability of primitive hematopoietic cells. Herein, this assay was performed with cells lacking LINC00152. Knockdown of LINC00152 led to a significant decrease in the colony formation capacity of CD34⁺ cells derived from three AML patients (Figures 3B–D), indicating that LINC00152 regulates the self-renewal of LSCs.

LINC00152 Regulates LSC Chemoresistance Via PARP1
Chemotherapy based on doxorubicin, an anthracycline, remains the standard line of treatment for leukemia (21). As previously described, chemoresistant LSCs partially induce leukemia relapse (3, 4). Whether LINC00152 can regulate the chemoresistance of LSCs was next investigated. The drug sensitivity curve indicated that LINC00152 knockdown markedly reduced the chemoresistance of K562 cells to doxorubicin (Figure 4A).

PARP1 has been reported to play an important role in DNA damage repair, and its expression is correlated with poor prognosis in AML (22). Moreover, PARP1 inhibition has exhibited the potential to enhance immunotherapy efficacy in AML (23). Thus, whether LINC00152 can regulate the chemoresistance of LSCs through PARP1 was investigated. qRT-PCR analysis confirmed that PARP1 expression in AML cells was significantly decreased upon LINC00152 knockdown (Figures 4B, C). Moreover, PARP1 was found to be highly expressed in CD34⁺CD38⁻ subpopulation compared with CD34⁺CD38⁺ cells derived from five AML patients (P = 0.0024) (Figure 4D). GEPIA further showed that the expression of LINC00152 was highly correlated with that of PARP1 (Figure 4E). Publicly available microarray data sets were also used to compare PARP1 expression between CD34⁺ and CD34⁻ cells in AML patients. Overall, PARP1 was found to be highly expressed in CD34⁺ cells (paired CD34⁺ vs. CD34⁻ subpopulations from 44 AML patients; GSE30029) (Figure 4F), as well as in CD34⁺CD38⁻ cells, compared with CD34⁺CD38⁺ cells (CD34⁺CD38⁻ subpopulations from 54 AML patients vs. CD34⁺CD38⁺ cells from 69 AML patients; GSE76008) (Figure 4G). Accordingly, PARP1 overexpression was associated with poor prognosis in AML patients (Figure 4H). Altogether, these data suggest that LINC00152 modulates the chemoresistance of AML through PARP1.

To further explore the potential mechanism through which LINC00152 and PARP1 modulate the chemoresistance of LSCs, Gene Ontology (GO) analysis via gene set enrichment analysis was
performed. The results of GO analysis showed that both LINC00152 and PARP1 were enriched in processes associated with DNA damage repair-related signaling, such as nucleotide-excision repair preincision complex stabilization, nucleotide-excision repair, DNA duplex unwinding, and global genome nucleotide-excision repair (GSE76009) (Figures 5A–F and Table 1).

DISCUSSION

LSCs are the most important contributors toward drug resistance and disease relapse in AML, with the proportion of LSCs in patients with AML being closely related to poor prognosis (20). A better understanding of the regulatory mechanisms of LSCs is necessary to effectively combat AML. In recent years, IncRNAs have been reported to play a key role in the growth and differentiation of cancer stem cells, in addition to being involved in cancer metastasis and drug resistance development (24, 25). Hence, the field of IncRNAs has attracted increasing attention, with drug development targeting IncRNAs emerging as a new direction. Theoretically, targeting IncRNAs can be achieved through blocking or knockdown by either antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs). However, the specific transport of ASOs or siRNAs to target cells and ensuring their stability remain considerably challenging (26).

In this study, it was confirmed that CD34+CD38− cells from AML patients possess strong LSC characteristics and tumor formation potential. Moreover, high expression of LINC00152 was found to be significantly correlated with the poor prognosis of AML patients. Indeed, LINC00152 expression was significantly correlated with that of 15 genes within 17 biomarker genes, which could accurately determine the drug resistance of AML patients. Furthermore, the present experimental data revealed that LINC00152 expression was significantly increased in CD34+CD38− cells and that its knockdown significantly reduced the colony formation ability of LSCs obtained from three AML patients. Taken together, these data indicate that the self-renewal ability of LSCs is greatly modulated by LINC00152, but the underlying mechanism requires further clarification.

LINC00152 is a large intergenic noncoding RNA with a length of 852 bp, located on chromosome 11.2 of genome 2 (16). Recent studies have shown that LINC00152 is highly expressed in various tumors, such as glioma, non-small cell lung cancer, and gastric cancer. Upregulated LINC00152 interacts with several signaling pathways,
FIGURE 2 | Correlation between LINC00152 expression and leukemia stem cell (LSC)-associated gene expression. LSC17 biomarker gene profile and LINC00152 expression were analyzed based on a publicly available data set (GSE76009) by gene expression profiling interactive analysis.
thereby promoting inflammatory responses as well as tumor cell proliferation, invasion, and metastasis (27–30). Recent studies have also reported that LINC00152 knockdown suppresses proliferation, accelerates apoptosis, and induces cycle arrest in AML cells (18).

Herein, the expression of PARP1 was found to be significantly decreased when LINC00152 was downregulated. PARP1 is mainly involved in DNA damage repair and is overexpressed in cancer stem cells. Previous studies have reported that high PARP1 expression is associated with poor AML prognosis (3) and the treatment with the PARP1 inhibitor enhances anti-AML effects (22). This is consistent with the results presented herein, which demonstrate that PARP1 is highly expressed in LSCs and that its expression is significantly correlated with that of LINC00152 in AML. Additionally, the findings revealed that high PARP1 expression was correlated with poor overall survival in AML. Moreover, along with the knockdown of LINC00152, PARP1 expression was significantly decreased, which in turn increased the sensitivity of cancer cells to the DNA damaging agent doxorubicin. Consistently, GO analysis showed that genes of LINC00152 and PARP1 were mainly enriched in processes associated with DNA damage repair-related signaling, such as nucleotide-excision repair, preincision complex stabilization, nucleotide-excision repair, DNA duplex unwinding, and global genome nucleotide-excision repair. Chemotherapy is the standard treatment for AML; however, the prognosis of AML patients who relapse remains poor. Our study will be useful for exploring novel targets to induce DNA damage and perturb cellular DNA damage repair. However, our results contrast with data from breast cancer (31), in which lncRNA H19 overexpression promoted doxorubicin resistance by downregulating PARP1 expression. Therefore, the detailed regulatory network of LINC00152 and PARP1 in AML needs to be further explored.

lncRNAs display significant expression variability and subcellular localization diversity. Accumulating evidence shows that a novel regulatory mechanism exists between lncRNAs and microRNAs. lncRNAs can act as endogenous molecular sponges to compete for the targets of the microRNAs, thereby negatively regulating the expression of microRNAs. For example, Chen et al. reported that the lncRNA UICLM could function as a competing endogenous RNA (ceRNA) for miR-215 in colorectal cancer cells to regulate the expression of ZEB1 (32), and Li et al. demonstrated that lncRNA ZFAS1 functions as an oncogene in hepatocellular carcinoma progression by binding to miR-150 and abrogating its tumor-suppressive function (33). In particular, it has been reported that LINC00152 acts as a ceRNA for miR-185-3p and miR-632 to regulate FSCN1 expression in colorectal cancer (34), and recent studies have reported that ectopically expressed LINC00152 accelerates AML proliferation and targets the miR-193a/CDK9 axis to exert its effect (18). Since PARP1 is a major downstream target of miR-181a (35), LINC00152 may also regulate PARP1 through microRNAs. Furthermore, posttranslational modifications of PARP1, such as mono (ADP-ribosyl)-ation (36, 37),
FIGURE 4 | LINC00152 regulates chemoresistance of leukemia stem cells (LSCs) via PARP1. (A) Doxorubicin sensitivity assay after LINC00152 knockdown in K562 cells. (B) PARP1 mRNA level after LINC00152 knockdown compared with control acute myeloid leukemia (AML) cells (*P < 0.05, **P < 0.01). (C) PARP1 expression at the protein level after LINC00152 knockdown compared with control AML cells. (D) PARP1 expression in CD34−CD38− and CD34−CD38+ cells derived from five AML patients. Data are represented as the mean ± SD of three independent experiments (**P < 0.01). (E) Expression of LINC00152 was correlated with that of PARP1 in AML based on a publicly available data set by gene expression profiling interactive analysis. (F) PARP1 expression in paired CD34+ cells vs. CD34− cells (GSE30029, ***P < 0.001). (G) PARP1 expression in CD34−CD38− vs. CD34−CD38+ cells (GSE76008, ***P < 0.001). (H) Correlation between overall survival of AML patients and PARP1 expression based on a publicly available data set (GSE76009) by gene expression profiling interactive analysis.
FIGURE 5 | Both LINC00152 and PARP1 expression correlated with DNA damage repair in acute myeloid leukemia. High expression of LINC00152 and PARP1 individually enriched the genes associated with nucleotide-excision repair, preincision complex stabilization (A, B), nucleotide-excision repair, DNA duplex unwinding (C, D), and global genome nucleotide-excision repair (E, F).
phosphorylation, methylation, and acetylation, can modulate its activity. Thus, LINC00152 may influence PARP1 posttranslational modification by binding to the enhancer of zeste homologue 2 (EZH2) (38) or participate in the phosphatidylinositol 3-kinase/AKT signaling pathway (39), which may also be important for PARP1 expression and activity.

In conclusion, our study shows that LINC00152 is highly expressed in LSCs and correlated with PARP1 expression, with the inhibition of LINC00152 leading to the downregulation of PARP1. Moreover, expression of LINC00152 or PARP1 is associated with poor prognosis in AML patients. Functionally, it can be speculated that LINC00152 regulates the self-renewal of LSCs and induces chemoresistance via PARP1. Therefore, these findings suggest that the LINC00152/PARP1 pathway could serve as a novel therapeutic target for AML.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Huashan Hospital. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

CC participated in the concept and design experiments, collect data, analyzed and explained the data, and wrote the manuscript. YW provided the study material. WG provided the study material. HH provided study material, concept and design experiments, financial support. WS participated in the concept and design experiments, wrote the manuscript, and finally approved the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by National Natural Scientific Foundation of China Grants (81802961).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.694021/full#supplementary-material
REFERENCES

1. Villarroya-A, Konieczny J, Cuminetti V, Arranz L. Leukemia Stem Cell Release From the Stem Cell Niche to Treat Acute Myeloid Leukemia. Front Cell Dev Biol (2020) 8:607. doi: 10.3389/fcell.2020.00607

2. Dohner H, Esteve E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and Management of AML in Adults: 2017 ELN Recommendations From an International Expert Panel. Blood (2017) 129:424–47. doi: 10.1182/blood-2016-08-733916

3. Paczulla AM, Rothfelder K, Rafel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NGK2D Ligands Defines Leukemia Stem Cells and Mediates Their Immune Evasion. Nature (2019) 572:254–9. doi: 10.1038/s41586-019-1410-1

4. Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, et al. Tracing the Origins of Relapse in Acute Myeloid Leukemia to Stem Cells. Nature (2017) 547:104–8. doi: 10.1038/nature22993

5. Laveder I, Boileau M, Neumann AL, Frison H, Mitchell A, Ng SWK, et al. Leukemic Stem Cell Signatures Identify Novel Therapeutics Targeting Acute Myeloid Leukemia. Blood Cancer J (2018) 8:52. doi: 10.1038/s41467-018-0087-2

6. Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, et al. Braveheart, a Long Noncoding RNA Required for DNA Repair Under Stress by Activating PARP1. J Biol Chem (2017) 292:15541–50. doi: 10.1074/jbc.M117.796761

7. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, et al. Genome-Wide Mapping and Characterization of Notch-Regulated Long Non-Coding RNA Linc00152 in Gastric Cancer and Its Clinical Significance. Tumour Biol (2015) 35(6):1710–21. doi: 10.1007/s13277-015-0305-2

8. Wang Y, Liu J, Bai H, Dang Y, Lv P, Wu S. Long Intergenic non-Coding RNA LINC00152 is a Positive Prognostic Factor for and Demonstrates Malignant Biological Behavior in Clear Cell Renal Cell Carcinoma. Am J Cancer Res (2016) 6(2):285–99.

9. Wang Y, Liu J, Bai H, Dang Y, Lv P, Wu S. Long Intergenic Non-Coding RNA LINC00152 Promotes Renal Cell Carcinoma Progression by Epigenetically Suppressing P16 and Negatively Regulates mir-205. Am J Cancer Res (2017) 7(2):312–22.

10. Wang Y, Zhou D, Li P, Yang F, Gao XQ. Long Non-Coding RNA H19 Regulates Proliferation and Doxorubicin Resistance in MCF-7 Cells by Targeting PARP1. Bioenergetics (2020) 11:536–46. doi: 10.1007/s13404-020-17615-2

11. Chen DL, Lu YX, Zhang JX, Wei XL, Wang F, Zeng ZL, et al. Long Non-Coding RNA LINC00152 Is a Positive Prognostic Factor for and Demonstrates Malignant Biological Behavior in Clear Cell Renal Cell Carcinoma. Cancer Cell Int (2012) 12:60. doi: 10.1186/1475-2861-12-60

12. Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A, et al. SIRT6 Promotes Reduced Immunogenicity, and Impaired Dendritic Cell Transformation in Acute Myeloid Leukemia. Nature (2020) 580:433–7. doi: 10.1038/s41586-020-20162-1

13. Cui et al. Role of LINC00152 in LSCs
Zhang L, Wang Y, Su H. Long Non-Coding RNA LINC00152/miR-613/CD164 Axis Regulates Cell Proliferation, Apoptosis, Migration and Invasion in Glioma via PI3K/AKT Pathway. Neoplasma (2020) 67:762–72. doi: 10.4149/neco_2020_190706N598

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.